• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials.

作者信息

Gentile Massimo, Specchia Giorgina, Derudas Daniele, Galli Monica, Botta Cirino, Rocco Stefano, Conticello Concetta, Califano Catello, Giuliani Nicola, Mangiacavalli Silvia, Attingenti Enrico, Lombardo Alessandra, Brunori Marino, Rossi Elena, Antonioli Elisabetta, Ria Roberto, Zambello Renato, Di Renzo Nicola, Mele Giuseppe, Marcacci Gianpaolo, Musto Pellegrino, Capalbo Silvana, Cascavilla Nicola, Cerchione Claudio, Belotti Angelo, Criscuolo Clelia, Uccello Giuseppina, Curci Paola, Vigna Ernesto, Fraticelli Vincenzo, Vincelli Donatella, Bonalumi Angela, Siniscalchi Agostina, Stocchi Raffaella, Martino Massimo, Ballanti Stelvio, Gangemi Dominella, Gagliardi Alfredo, Gamberi Barbara, Pompa Alessandra, Recchia Anna Grazia, Tripepi Giovanni, Pitino Annalisa, Frigeri Ferdinando, Consoli Ugo, Bringhen Sara, Zamagni Elena, Patriarca Francesca, De Stefano Valerio, Di Raimondo Francesco, Palmieri Salvatore, Petrucci Maria Teresa, Offidani Massimo, Boccadoro Mario, Cavo Michele, Morabito Fortunato

机构信息

Hematology Unit and Biotechnology Research Unit, Azienda Ospedaliera of Cosenza, Cosenza.

Hematology Section, University of Bari.

出版信息

Haematologica. 2021 Jan 1;106(1):291-294. doi: 10.3324/haematol.2019.241513.

DOI:10.3324/haematol.2019.241513
PMID:32107338
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7776255/
Abstract
摘要

相似文献

1
Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials.埃罗妥珠单抗、来那度胺和地塞米松作为多发性骨髓瘤患者的挽救治疗：意大利多中心非对照临床试验之外300例患者的回顾性临床经验
Haematologica. 2021 Jan 1;106(1):291-294. doi: 10.3324/haematol.2019.241513.
2
Successful Retreatment with Elotuzumab for Multiple Myeloma with Extramedullary Relapse while Being Treated with Lenalidomide and Dexamethasone.
Pathol Oncol Res. 2020 Jul;26(3):1993-1995. doi: 10.1007/s12253-019-00725-x. Epub 2019 Aug 22.
3
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials.依洛珠单抗联合来那度胺和地塞米松治疗复发/难治性多发性骨髓瘤：319 例回顾性临床经验的 3 年随访，该研究在对照临床试验之外进行。
Hematol Oncol. 2022 Oct;40(4):704-715. doi: 10.1002/hon.3031. Epub 2022 Jun 1.
4
Elotuzumab in Combination with Lenalidomide and Dexamethasone for Treatment-resistant Immunoglobulin Light Chain Amyloidosis With Multiple Myeloma.埃罗妥珠单抗联合来那度胺和地塞米松治疗难治性免疫球蛋白轻链淀粉样变性伴多发性骨髓瘤
Clin Lymphoma Myeloma Leuk. 2019 Jan;19(1):e33-e36. doi: 10.1016/j.clml.2018.08.021. Epub 2018 Sep 5.
5
Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study.埃罗妥珠单抗联合来那度胺和地塞米松治疗复发多发性骨髓瘤患者：随机、开放标签、1b-2期剂量递增研究的最终2期结果
Lancet Haematol. 2015 Dec;2(12):e516-27. doi: 10.1016/S2352-3026(15)00197-0. Epub 2015 Nov 16.
6
Once Monthly Elotuzumab and Lenalidomide Plus Dexamethasone for Multiple Myeloma: A Multicenter Observation Study.每月一次埃罗妥珠单抗联合来那度胺及地塞米松治疗多发性骨髓瘤：一项多中心观察性研究
Acta Haematol. 2023;146(2):125-136. doi: 10.1159/000528700. Epub 2022 Dec 20.
7
Elotuzumab in multiple myeloma.埃罗妥珠单抗治疗多发性骨髓瘤
Expert Opin Biol Ther. 2023 Jan;23(1):7-10. doi: 10.1080/14712598.2022.2145882. Epub 2022 Nov 14.
8
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients.来那度胺和地塞米松联合埃罗妥珠单抗与卡非佐米对比作为挽救疗法治疗多发性骨髓瘤患者的调整后比较。
Eur J Haematol. 2022 Mar;108(3):178-189. doi: 10.1111/ejh.13723. Epub 2021 Nov 9.
9
Pembrolizumab, lenalidomide and dexamethasone post autologous transplant in patients with high-risk multiple myeloma.帕博利珠单抗、来那度胺和地塞米松用于高危多发性骨髓瘤患者自体移植后治疗
Am J Hematol. 2021 Nov 1;96(11):E430-E433. doi: 10.1002/ajh.26333. Epub 2021 Sep 17.
10
Elotuzumab in the treatment of relapsed and refractory multiple myeloma.依洛尤单抗治疗复发/难治性多发性骨髓瘤。
Future Oncol. 2021 May;17(13):1581-1591. doi: 10.2217/fon-2020-1088. Epub 2021 Jan 22.

引用本文的文献

1
A network meta-analysis of randomized clinical trials in lenalidomide-exposed or -refractory multiple myeloma patients.来那度胺治疗的或难治性多发性骨髓瘤患者随机临床试验的网络荟萃分析。
ESMO Open. 2025 Jul 15;10(8):105514. doi: 10.1016/j.esmoop.2025.105514.
2
Lenalidomide based triplets in relapsed/refractory multiple myeloma: analysis of the Czech Myeloma Group.来那度胺为基础的三联疗法用于复发/难治性多发性骨髓瘤：捷克骨髓瘤研究组的分析
BMC Cancer. 2025 Apr 9;25(1):651. doi: 10.1186/s12885-025-14087-y.
3
Monoclonal Antibodies in Relapsed-Refractory Multiple Myeloma.
复发难治性多发性骨髓瘤中的单克隆抗体
Pharmaceuticals (Basel). 2025 Jan 22;18(2):145. doi: 10.3390/ph18020145.
4
Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials.isatuximab、泊马度胺和地塞米松作为多发性骨髓瘤患者的挽救治疗：意大利多中心非对照临床试验外270例患者的回顾性临床经验
Haematologica. 2025 Apr 1;110(4):1028-1033. doi: 10.3324/haematol.2024.286658. Epub 2024 Nov 28.
5
Safety and Effectiveness of Elotuzumab in Japanese Patients with Relapsed/Refractory Multiple Myeloma: A Post-marketing Surveillance Study.Elotuzumab 在日本复发/难治性多发性骨髓瘤患者中的安全性和有效性：一项上市后监测研究。
Intern Med. 2024 Nov 15;63(22):3039-3048. doi: 10.2169/internalmedicine.2487-23. Epub 2024 Mar 18.
6
miRNAs and Multiple Myeloma: Focus on the Pathogenesis, Prognosis, and Drug Resistance.miRNAs 与多发性骨髓瘤：关注发病机制、预后和耐药性。
Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231202391. doi: 10.1177/15330338231202391.
7
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials.依洛尤单抗联合泊马度胺和地塞米松治疗复发/难治性多发性骨髓瘤：在对照临床试验之外的 200 例多中心、回顾性、真实世界研究中的经验。
Haematologica. 2024 Jan 1;109(1):245-255. doi: 10.3324/haematol.2023.283251.
8
Lenalidomide-based triplet regimens in first relapsed multiple myeloma patients: real-world evidence from a propensity score matched analysis.来那度胺为基础的三联方案治疗首次复发的多发性骨髓瘤患者：来自倾向评分匹配分析的真实世界证据。
Haematologica. 2023 Mar 1;108(3):833-842. doi: 10.3324/haematol.2022.281342.
9
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials.接受埃罗妥珠单抗或卡非佐米联合来那度胺和地塞米松作为挽救治疗的真实世界复发/难治性多发性骨髓瘤患者的生存风险评分：919例非临床试验病例分析
Front Oncol. 2022 Jul 18;12:890376. doi: 10.3389/fonc.2022.890376. eCollection 2022.
10
Network meta-analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant.随机临床试验的网络荟萃分析：不适合移植的多发性骨髓瘤患者一线治疗的疗效和安全性。
Hematol Oncol. 2022 Dec;40(5):987-998. doi: 10.1002/hon.3041. Epub 2022 Jul 11.